Alto Neuroscience Inc. Share Price
NYSE: ANRO | Small CapAlto Neuroscience Inc. Stock Performance
Open $28.14 | Prev. Close $28.05 | Circuit Range N/A |
Day Range $28.13 - $29.44 | Year Range $3.00 - $29.44 | Volume 15,633 |
Average Traded $28.63 |
Alto Neuroscience Inc. Share Price Today
As of 9 August 2026, Alto Neuroscience Inc.'s share price is $28.47. The stock opened at $28.14, compared to its previous close of $28.05. During today's trading session, Alto Neuroscience Inc.'s share price traded between $28.13 and $29.44, with an average price of $28.78. Over the past 52 weeks, the stock has recorded a high of $29.44 and a low of $3.00. In terms of performance, Alto Neuroscience Inc.'s share price has risen by 45.40% over the last six months and is up 665.32% on a year-on-year basis.
Alto Neuroscience Inc. Share Price Chart
Alto Neuroscience Inc. Stock Fundamentals & Key Indicators
Market Cap $821.42M | PE Ratio (TTM) -13.00 | Dividend Yield N/A |
EPS (TTM) $-2.19 | Revenue (TTM) N/A | Return On Equity (TTM) -41.84% |
Profit Margin N/A | Debt to Equity 0.07 | Quarterly Earnings Growth YoY 15.50% |
Alto Neuroscience Inc. Quarterly Profit & Loss
All figures in USD
About Alto Neuroscience Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California.
Alto Neuroscience Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $26.65 | $28.02 | +3.39% |
Jul 2026 | $26.29 | $27.10 | +2.57% |
Jun 2026 | $20.05 | $26.42 | +31.57% |
May 2026 | $25.26 | $20.08 | -22.02% |
Apr 2026 | $22.57 | $25.75 | +14.17% |
Mar 2026 | $19.16 | $22.55 | +15.19% |
Feb 2026 | $14.59 | $19.58 | +26.73% |
Jan 2026 | $17.57 | $15.45 | -13.32% |
Dec 2025 | $13.27 | $17.82 | +29.03% |
Nov 2025 | $14.10 | $13.81 | -2.75% |
Oct 2025 | $4.08 | $14.21 | +254.24% |
Sep 2025 | $3.74 | $4.01 | +7.80% |
ANRO Share Price FAQs
What is Alto Neuroscience Inc. share price today?
What is the 52 week high and 52 week low of Alto Neuroscience Inc. stock?
What is ANRO's market capitalisation today?
What is ANRO's net income for the last quarter?
What is the 5 year returns of ANRO?
What is the high & low stock price of ANRO today?
Can I buy ANRO shares in India?